Literature DB >> 6593112

Diagnostic efficacy of screening tests for hereditary hemochromatosis.

S Borwein, C N Ghent, L S Valberg.   

Abstract

Hereditary hemochromatosis is transmitted as an autosomal recessive trait. Analyses of pedigrees suggest that the frequency of disease (proportion of homozygous individuals) in the general population is approximately 0.3% and that approximately 11% of the population are heterozygous. The genotype of 194 persons in 38 pedigrees was determined by HLA-A and HLA-B haplotyping. Likelihood analysis was then used to appraise the transferrin saturation test when used alone and in combination with the serum ferritin test to detect homozygosity and heterozygosity in these pedigrees. A single cut-off point of 55% for transferrin saturation and a cut-off point at the 90th percentile for the serum ferritin level were adequate for the detection of hemochromatosis if homozygosity was considered to be present when the results of one or both tests were positive. To further assess the value of the transferrin saturation test the percentages were stratified into five intervals. A percentage transferrin saturation of 75 or greater and a serum ferritin level above the 90th percentile ruled in homozygosity, whereas a percentage transferrin saturation of less than 55 and a serum ferritin level at or below the 90th percentile ruled it out with confidence. The probability of heterozygosity rose to 90% when the percentage transferrin saturation was between 35 and 55 and the serum ferritin level was at or below the 90th percentile. The use of five cut-off points allowed the probability of homozygosity and heterozygosity in a pedigree to be estimated for all values of transferrin saturation. Although these screening tests are not recommended for use in the general population, they may be worth while in selected groups of patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6593112      PMCID: PMC1483766     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  6 in total

1.  Serum ferritin and the iron status of Canadians.

Authors:  L S Valberg; J Sorbie; J Ludwig; O Pelletier
Journal:  Can Med Assoc J       Date:  1976-03-06       Impact factor: 8.262

2.  Hereditary hemochromatosis. Diagnosis in siblings and children.

Authors:  C Q Edwards; M Carroll; P Bray; G E Cartwright
Journal:  N Engl J Med       Date:  1977-07-07       Impact factor: 91.245

3.  Screening for iron overload using transferrin saturation.

Authors:  K S Olsson; K Eriksson; B Ritter; P A Heedman
Journal:  Acta Med Scand       Date:  1984

4.  Hereditary hemochromatosis. Analysis of laboratory expression of the disease by genotype in 18 pedigrees.

Authors:  M M Dadone; J P Kushner; C Q Edwards; D T Bishop; M H Skolnick
Journal:  Am J Clin Pathol       Date:  1982-08       Impact factor: 2.493

5.  Genetic and phenotypic expression of hemochromatosis in Canadians.

Authors:  S T Borwein; C N Ghent; P R Flanagan; M J Chamberlain; L S Valberg
Journal:  Clin Invest Med       Date:  1983       Impact factor: 0.825

6.  A radioimmunoassay for serum ferritin.

Authors:  A W Luxton; W H Walker; J Gauldie; A M Ali; C Pelletier
Journal:  Clin Chem       Date:  1977       Impact factor: 8.327

  6 in total
  6 in total

1.  Hypogonadotropic hypogonadism in idiopathic hemochromatosis: evidence for combined hypothalamic and pituitary involvement.

Authors:  K Siminoski; M D'Costa; P G Walfish
Journal:  J Endocrinol Invest       Date:  1990-11       Impact factor: 4.256

2.  Screening for hemochromatosis?

Authors:  F A Lederle
Journal:  J Gen Intern Med       Date:  1989 Jan-Feb       Impact factor: 5.128

3.  Usefulness of erythrocyte ferritin analysis in hereditary hemochromatosis.

Authors:  M K Cruickshank; J Ninness; A Curtis; R M Barr; P R Flanagan; C N Ghent; L S Valberg
Journal:  CMAJ       Date:  1987-06-15       Impact factor: 8.262

4.  Familial screening for genetic haemochromatosis by means of DNA markers.

Authors:  J Yaouanq; A el Kahloun; M Chorney; A M Jouanolle; V Mauvieux; M Perichon; M Blayau; P Pontarotti; J Y Le Gall; V David
Journal:  J Med Genet       Date:  1992-05       Impact factor: 6.318

5.  Neurofibromatosis type 1 (NF1): knowledge, experience, and reproductive decisions of affected patients and families.

Authors:  C M Benjamin; A Colley; D Donnai; H Kingston; R Harris; L Kerzin-Storrar
Journal:  J Med Genet       Date:  1993-07       Impact factor: 6.318

6.  Disposal of iron by a mutant form of lipocalin 2.

Authors:  Jonathan Barasch; Maria Hollmen; Rong Deng; Eldad A Hod; Peter B Rupert; Rebecca J Abergel; Benjamin E Allred; Katherine Xu; Shaun F Darrah; Yared Tekabe; Alan Perlstein; Rebecca Wax; Efrat Bruck; Jacob Stauber; Kaitlyn A Corbin; Charles Buchen; Vesna Slavkovich; Joseph Graziano; Steven L Spitalnik; Guanhu Bao; Roland K Strong; Andong Qiu
Journal:  Nat Commun       Date:  2016-10-31       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.